EXPEDITED PUBLICATION: LATE-BREAKING CLINICAL TRIAL
Proof of ConceptHemodynamic Response to Long-Term Partial Ventricular Support With the Synergy Pocket Micro-Pump
Bart Meyns, MD, PhD*,
Stefan Klotz, MD, PhD ,
Andre Simon, MD ,
Walter Droogne, MD*,
Filip Rega, MD*,
Bartley Griffith, MD ,
Robert Dowling, MD||,
Mark J. Zucker, MD¶ and
Daniel Burkhoff, MD, PhD#,**,*
* University of Leuven, Leuven, Belgium
University of Münster, Münster, Germany
Hannover Medical School, Hannover, Germany
University of Maryland, Baltimore, Maryland
|| Univeristy of Louisville, Louisville, Kentucky
¶ Newark Beth Israel Medical Center, Newark, New Jersey
# CircuLite, Inc., Saddle Brook, New Jersey
** Columbia University, New York, New York
Manuscript received March 2, 2009;
revised manuscript received April 3, 2009,
accepted April 6, 2009.
* Reprint requests and correspondence: Dr. Daniel Burkhoff, Division of Cardiology, Columbia University, 177 Fort Washington Avenue, New York, New York 10032 (Email: db59{at}columbia.edu).
Objective: The purpose of this study was to test the hemodynamic effects of partial ventricular support in patients with advanced heart failure.
Background: The use of current left ventricular assist devices (VADs) that provide full circulatory support is restricted to critically ill patients because of associated risks. Smaller, less-invasive devices could expand VAD use to a larger pool of less-sick patients but would pump less blood, providing only partial support.
Methods: The Synergy Pocket Micro-pump device (CircuLite, Inc., Saddle Brook, New Jersey) pumps 3.0 l/min, is implanted (off pump) via a mini-thoracotomy, and is positioned in a right subclavicular subcutaneous pocket (like a pacemaker). The inflow cannula inserts into the left atrium; the outflow graft connects to the right subclavian artery.
Results: A total of 17 patients (14 men), age 53 ± 9 years with ejection fraction 21 ± 6%, mean arterial pressure 73 ± 7 mm Hg, pulmonary capillary wedge pressure 29 ± 6 mm Hg, and cardiac index 1.9 ± 0.4 l/min/m2 received an implant. Duration of support ranged from 6 to 213 (median 81) days. In addition to demonstration of significant acute hemodynamic improvements in the first day of support, 9 patients underwent follow-up right heart catheterization at 10.6 ± 6 weeks. These patients showed significant increases in arterial pressure (67 ± 8 mm Hg vs. 80 ± 9 mm Hg, p = 0.01) and cardiac index (2.0 ± 0.4 l/min/m2 vs. 2.8 ± 0.6 l/min/m2, p = 0.01) with large reductions in pulmonary capillary wedge pressure (30 ± 5 mm Hg vs. 18 ± 5 mm Hg, p = 0.001).
Conclusions: Partial support appears to interrupt the progressive hemodynamic deterioration typical of late-stage heart failure. If proven safe and durable, this device could be used in a relatively large population of patients with severe heart failure who are not sick enough to justify use of currently available full support VADs. (Safety and Performance Evaluation of CircuLite Synergy; NCT00878527
[ClinicalTrials.gov]
).
Key Words: left ventricular device hemodynamics heart failure partial support
|
Abbreviations and Acronyms
| | CT = computed tomography | | INR = international normalized ratio | | LVAD = left ventricular assist device |
|
Related Article
-
Partial Mechanical Cardiac Support: Part of the Solution or Part of the Problem?
- Patrick M. McCarthy
J. Am. Coll. Cardiol. 2009 54: 87-88.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
P. M. McCarthy
Partial mechanical cardiac support part of the solution or part of the problem?
J. Am. Coll. Cardiol.,
June 30, 2009;
54(1):
87 - 88.
[Full Text]
[PDF]
|
 |
|
|